<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9218738</article-id><article-id pub-id-type="pmc">2223781</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sekine</surname><given-names>I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nishiwaki</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kakinuma</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kubota</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hojo</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ohmatsu</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yokozaki</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Goto</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Miyamoto</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Takafuji</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kodama</surname><given-names>T.</given-names></name></contrib></contrib-group><aff>Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa-city, Chiba, Japan.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>1</issue><fpage>90</fpage><lpage>92</lpage><abstract><p>Thirty-three patients with lung cancer receiving 80 mg m(-2) cisplatin were treated with high-dose dexamethasone (32 mg m(-2) on days 1-3, 16 mg m(-2) on day 4 and 8 mg m(-2) on day 5) combined with granisetron on day 1 and metoclopramide on days 2-5. Twenty-eight (85%) patients had no nausea or vomiting on day 1, and 16 (48%) achieved total control on days 1-5 with acceptable toxicity. High-dose dexamethasone for cisplatin-induced delayed emesis should be further evaluated in a phase III trial.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00165-0094.tif" xlink:title="scanned-page" xlink:role="90" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00165-0095.tif" xlink:title="scanned-page" xlink:role="91" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00165-0096.tif" xlink:title="scanned-page" xlink:role="92" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

